Remi Bader says her binge eating worsened after stopping Ozempic

In January 2023, television personality and plus-size creator Remi Bader told People that she had been prescribed Ozempic while prediabetic, and that her binge eating became significantly worse after she stopped taking it. Her account was one of the earliest widely read stories connecting GLP-1 medications to disordered eating patterns ^[1].

Ozempic is the brand name for semaglutide, a drug approved by the FDA to treat type 2 diabetes. Weight loss is a common side effect, so the drug is often prescribed off-label for that purpose even though Novo Nordisk, the company that makes it, has said it does not support off-label use of its medications ^[1].

Bader's story arrived early in a wave of celebrity and public accounts about GLP-1 drugs that has continued for years. Some of those accounts describe struggles with appetite and mood that echo parts of what Bader described. Reality star Savannah Chrisley said she stopped an earlier GLP-1 medication because it changed her relationship with food. "I love food," she said on her podcast. "So when I'm on the shot and I can't eat, I'm like, 'I really love food.'" She later switched to a different drug, tirzepatide, and said it caused fewer side effects for her ^[1].

Chrissy Teigen told a podcast audience in 2025 that she turned to Ozempic after a 2020 miscarriage, describing it as a response to "deep depression" over her body at the time. She said she found the drug's effect on hunger difficult to manage. "It was frustrating for me because I know that logically you need food to have energy," she said ^[1]. Podcast host Bunnie XO told People in December 2025 that she had "a bout of suicidal ideation" while taking a GLP-1 drug, which she said was prompted by a family history of diabetes ^[1]. These accounts do not directly confirm or explain what Bader experienced, but they show that public figures have described a range of appetite, mood, and eating-related effects while on and off these medications.

The available sources do not include clinical research on GLP-1 drugs and binge eating disorder specifically, so it is not yet known from this reporting how common or severe such a rebound effect might be, or what mechanism might drive it.

Why it matters for patients

Bader's account, and the similar experiences later described by other public figures, highlight that stopping a GLP-1 medication can coincide with changes in eating behavior for some people. This matters for patients weighing whether to start, continue, or stop these drugs, since appetite and eating patterns are part of what the medications are designed to affect ^[1]. At the same time, these are individual accounts from public figures, not controlled studies, and the sources here do not offer data on how often binge eating changes after stopping a GLP-1 or who might be more likely to experience it.

The broader set of celebrity accounts collected in these sources also shows that experiences with GLP-1 drugs vary widely, from people who describe them as life-changing to people who describe difficult side effects, including on mood ^[1]. That range underscores why individual medical history, including any history of disordered eating, may be relevant context for anyone discussing these medications with a doctor.

What happens next

The sources reviewed do not include any planned studies or regulatory reviews specifically addressing GLP-1 drugs and binge eating disorder, so no dated next steps on that question are known from this reporting.